Nobel Prize for novel cancer therapies
4 October 2018
Two of the men responsible for the discovery and development of checkpoint inhibitors, therapies that revolutionised the way metastatic melanoma patients are treated, extending lives and improving quality of life for countless patients, were awarded this year’s Nobel Prize in Physiology or Medicine.
Professor James P. Allison from MD Anderson Cancer Centre, and Professor Tasuku Honjo from Kyoto University were jointly awarded the Nobel Prize for their separate work from the early 1990’s, where they each discovered a different protein that plays a major role in regulating the immune system.
The immune system is a balancing act – it is constantly trying to fight off foreign invaders, like viruses and bacteria, without harming the body – that relies heavily on an intricate system of brakes and accelerators. Sometimes the balance is off, resulting in autoimmune diseases where the immune system attacks the body, or diseases like cancer, where the immune system does not recognise that there is anything amiss.
Both Professor Allison and Professor Honjo discovered molecules that act as a brake in the immune system, halting its action and allowing cancers to grow. In Professor Allison’s research, he showed that blocking the molecule he discovered, CTLA-4, could switch off the brake, allowing the immune system to recognise a tumour and attack it. His work lead to the development of the melanoma fighting drug ipilumimab. Professor Honjo discovered the protein PD-1, and found that blocking it allows the immune system to recognise cancer as an invader and mount an immune response. This led to the manufacture of the immunotherapies nivolumab and pembrolizumab.
Ipilumimab (Yervoy), nivolumab (Opdivo) and pembrolizumab (Keytruda) are now used extensively to treat metastatic melanoma, working to help patient’s own bodies to recognise and fight the disease. Since these treatments have become available, melanoma patients have a better prognosis than ever before.
The two men will receive their Nobel Prizes at a formal ceremony in Stockholm in December. Five different Nobel Prizes are awarded every year, with the Nobel Prize in Physiology or Medicine given to up to three people who have made outstanding discoveries in the fields of medicine or the life sciences. Previous Nobel laureates include three of the men responsible for the discovery of DNA, and the three men who discovered penicillin.
Photograph: Niklas Elmehed/Twitter:NobelPrize
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.